世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の網膜治療薬市場 2018-2022年

Global Retinal Drugs Market 2018-2022

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年4月US$2,500
シングルユーザライセンス
133

サマリー

このレポートは世界の網膜治療薬市場を調査したTechNavioの調査報告書です。

Report Details

About Retinal Drugs

Retinal drugs are the medications that are used for the treatment of retinal diseases.

Technavio’s analysts forecast the global retinal drugs market to grow at a CAGR of 7.63% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the global retinal drugs market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, Global Retinal Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- ALLERGAN
- Bayer
- F. Hoffmann-La Roche
- Novartis
- Regeneron Pharmaceuticals
- Valeant Pharmaceuticals


Market driver
- Rise in the prevalence of retinal diseases
- For a full, detailed list, view our report

Market challenge
- High cost associated with retinal disease therapy
- For a full, detailed list, view our report

Market trend
- Development of innovative therapies
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY INDICATION
- Segmentation by indication
- Comparison by indication
- MD drugs
- DED drugs
- Others
- Market opportunity by indication
PART 08: MARKET SEGMENTATION BY DRUG CLASS
- Segmentation by drug class
- Anti-VEGF agents
- Corticosteroids
- Others
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Retinal drugs market in Americas
- Retinal drugs market in EMEA
- Retinal drugs market in APAC
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
- Development of innovative therapies
- Rise in demand for sustained-release ocular formulations
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS0
- Vendors covered
- Vendor classification
- Market positioning of vendors
- ALLERGAN
- Bayer
- F. Hoffmann-La Roche
- Novartis
- Regeneron Pharmaceuticals
- Valeant Pharmaceuticals
PART 16: APPENDIX
- List of abbreviations
- Exhibit 01: Parent market
- Exhibit 02: Global ophthalmic drugs market segmentation
- Exhibit 03: Market characteristics
- Exhibit 04: Market segments
- Exhibit 05: Market definition - Inclusions and exclusions checklist
- Exhibit 06: Market size 2017
- Exhibit 07: Validation techniques employed for market sizing 2017
- Exhibit 08: Global retinal drugs market - Market size and forecast 2017-2022 ($ mn)
- Exhibit 09: Global retinal drugs market - Year-over-year growth 2018-2022 (%)
- Exhibit 10: Five forces analysis 2017
- Exhibit 11: Five forces analysis 2022
- Exhibit 12: Bargaining power of buyers
- Exhibit 13: Bargaining power of suppliers
- Exhibit 14: Threat of new entrants
- Exhibit 15: Threat of substitutes
- Exhibit 16: Threat of rivalry
- Exhibit 17: Market condition - Five forces 2017
- Exhibit 18: Global retinal drugs market - Market share by indication 2017-2022 (%)
- Exhibit 19: Comparison by indication
- Exhibit 20: Global MD drugs market - Market size and forecast 2017-2022 ($ mn)
- Exhibit 21: Global MD drugs market - Year-over-year growth 2018-2022 (%)
- Exhibit 22: Global DED drugs market - Market size and forecast 2017-2022 ($ mn)
- Exhibit 23: Global DED drugs market - Year-over-year growth 2018-2022 (%)
- Exhibit 24: Global other retinal diseases drugs market - Market size and forecast 2017-2022 ($ mn)
- Exhibit 25: Global other retinal diseases drugs market - Year-over-year growth 2018-2022 (%)
- Exhibit 26: Market opportunity by indication
- Exhibit 27: Global retinal drugs market share by drug class 2017 (%)
- Exhibit 28: Major anti-VEGF agents approved in the market
- Exhibit 29: Major corticosteroids approved in the market
- Exhibit 30: Customer landscape
- Exhibit 31: Global retinal drugs market - Market share by geography 2017-2022 (%)
- Exhibit 32: Regional comparison
- Exhibit 33: Retinal drugs market in Americas - Market size and forecast 2017-2022 ($ mn)
- Exhibit 34: Retinal drugs market in Americas - Year-over-year growth 2018-2022 (%)
- Exhibit 35: Top 3 countries in Americas
- Exhibit 36: Retinal drugs market in EMEA - Market size and forecast 2017-2022 ($ mn)
- Exhibit 37: Retinal drugs market in EMEA - Year-over-year growth 2018-2022 (%)
- Exhibit 38: Top 3 countries in EMEA
- Exhibit 39: Retinal drugs market in APAC - Market size and forecast 2017-2022 ($ mn)
- Exhibit 40: Retinal drugs market in APAC - Year-over-year growth 2018-2022 (%)
- Exhibit 41: Top 3 countries in APAC
- Exhibit 42: Market opportunity
- Exhibit 43: Vendor landscape
- Exhibit 44: Landscape disruption
- Exhibit 45: Vendors covered
- Exhibit 46: Vendor classification
- Exhibit 47: Market positioning of vendors
- Exhibit 48: ALLERGAN - Overview
- Exhibit 49: ALLERGAN - Business segments
- Exhibit 50: ALLERGAN - Organizational developments
- Exhibit 51: ALLERGAN - Geographic focus
- Exhibit 52: ALLERGAN - Segment focus
- Exhibit 53: ALLERGAN - Key offering
- Exhibit 54: ALLERGAN - Key customers
- Exhibit 55: Bayer - Overview
- Exhibit 56: Bayer - Business segments
- Exhibit 57: Bayer - Organizational developments
- Exhibit 58: Bayer - Geographic focus
- Exhibit 59: Bayer - Segment focus
- Exhibit 60: Bayer - Key offerings
- Exhibit 61: Bayer - Key customers
- Exhibit 62: F. Hoffmann-La Roche - Overview
- Exhibit 63: F. Hoffmann-La Roche - Business segments
- Exhibit 64: F. Hoffmann-La Roche - Organizational developments
- Exhibit 65: F. Hoffmann-La Roche - Geographic focus
- Exhibit 66: F. Hoffmann-La Roche - Segment focus
- Exhibit 67: F. Hoffmann-La Roche - Key offerings
- Exhibit 68: F. Hoffmann-La Roche - Key customers
- Exhibit 69: Novartis - Overview
- Exhibit 70: Novartis - Business segments
- Exhibit 71: Novartis - Organizational developments
- Exhibit 72: Novartis - Geographic focus
- Exhibit 73: Novartis - Segment focus
- Exhibit 74: Novartis - Key offerings
- Exhibit 75: Novartis - Key customers
- Exhibit 76: Regeneron Pharmaceuticals - Overview
- Exhibit 77: Regeneron Pharmaceuticals - Business segments
- Exhibit 78: Regeneron Pharmaceuticals - Organizational developments
- Exhibit 79: Regeneron Pharmaceuticals - Geographic focus
- Exhibit 80: Regeneron Pharmaceuticals - Segment focus
- Exhibit 81: Regeneron Pharmaceuticals - Key offerings
- Exhibit 82: Regeneron Pharmaceuticals - Key customers
- Exhibit 83: Valeant Pharmaceuticals - Overview
- Exhibit 84: Valeant Pharmaceuticals - Business segments
- Exhibit 85: Valeant Pharmaceuticals - Organizational developments
- Exhibit 86: Valeant Pharmaceuticals - Geographic focus
- Exhibit 87: Valeant Pharmaceuticals - Segment focus
- Exhibit 88: Valeant Pharmaceuticals - Key offerings
- Exhibit 89: Valeant Pharmaceuticals - Key customers

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る